Introduction
Colorectal cancer (CRC) is the third most common cancer in the world, and its burden is expected to increase 60% by 2030 to more than 2.2 million new cases and 1.1 million deaths (1) (2) (3) . Current prognostic factors are still insufficient for identifying patients at high risk of recurrence after surgery for stage II and III disease. These patients may benefit from aggressive adjuvant treatment. It would also be desirable to identify patients at low risk of recurrence who may safely be spared the morbidity and expense of adjuvant interventions after surgery (4-7).
TP53, a well-known tumor suppressor gene, encodes a nuclear protein that is a nexus for responses to various cellular stresses. Activation of the p53 pathway results in cell cycle arrest, apoptosis, or senescence (8) . Inactivation of p53 is a key event in CRC progression and correlates with transitions from benign adenomas to malignant carcinomas (9) . Although many investigations have addressed the prognostic value of p53 in CRC patients, no consistent conclusions have been drawn (10, 11) . Cellular proliferation rate may be another tool to stratify CRC risk groups. The MIB-1 antibody recognizes an epitope on the Ki-67 cell cycle progression protein and is frequently used to measure proliferation or to predict behavior for many malignancies. In CRC patients, however, the Ki-67 index has not always had a significant association with clinical outcome (11) . Finally, antitumor immune responses portend a favorable outcome for many tumors (12) . Multiple cancer types implement an "immune shield" against inflammatory cell attack by expressing programmed death ligand 1 (PD-L1). This surface receptor on the tumor cell generates an immunosuppressive microenvironment and allows the tumor cell with foreign epitopes to escape immune-mediated destruction (13) . PD-L1 ligand binding to programmed death-1 (PD-1) receptors on T-cells results in suppression of CD-8+
antigen-specific cytotoxic cell proliferation and causes apoptosis of PD-1 positive lymphocytes.
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4 PD-L1 expression in tumor specimens is used as a predictive marker for tumor response to anti-PD-1 or anti-PD-L1 immunotherapy (14) (15) (16) . The present investigation was designed to assess the value of using p53 and Ki-67 as prognostic markers either alone or in combination with PD-L1 in patients with stage II and III CRC.
Materials and Methods

Patients
Tumor samples were obtained from 254 consecutive patients who had undergone surgical resection for CRC without preoperative treatment at the Fudan University Shanghai Cancer
Center (FUSCC) from 2007 through 2009. The inclusion criteria were as follows: primary sporadic colorectal adenocarcinoma (mucinous carcinoma and other less common variant types were excluded), 28-75 years of age, and no preoperative chemotherapy or radiotherapy (17) .
Patients were included if the final pathology report of the CRC included the tumor location, whether colo-cecal or recto-sigmoid, and tumor size by greatest dimension, whether lateral or radial. The patients were staged according to the American Joint Committee on Cancer/International Union against Cancer (AJCC/UICC) TNM staging system (2010, 7th edition) (18) . All the patients had advanced-stage colorectal cancer (≥ T2). Histologic grading (differentiation) was based on the 2010 WHO classification of tumors of the digestive system (4th edition) (19) . The study was carried out with the approval of the local Ethics Committee of FUSCC.
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Tissue Microarray and Immunohistochemistry
Tissue microarrays (TMA) were constructed from paraffin-embedded blocks of the 254 CRC primary tumors as previously described (17 (17) . IHC evaluation considered p53 and Ki-67 expression only in the nuclei of tumor cells (Figure 1 ). The interpretation of immunoreactivity for p53 was evaluated using the "hybrid scoring system" (H-score) criteria. An H-score was calculated as the sum of the product of the staining intensity in tumor cells (0, no staining; 1, weak staining; 2, moderate staining; 3, intense staining) and the proportion of cells showing that staining intensity (0-100%). If more than one staining intensity was present, the H-score was the sum of the h-scores for each intensity level.
Thus, the possible H-score ranged from 0 to 300 (20) . Currently there is no consensus cutoff for p53 immunohistochemistry in CRC. In this study, cutoff score for p53 positivity was optimized using receiver operating characteristic (ROC) curve analysis (Figure 2 ). An H-score ≥ 35 defined a positive p53 expression; and an H-score <35 defined a negative p53 expression. For
Ki-67 labeling index (LI), each TMA core was scored based on the percentage of positively stained malignant nuclei regardless of stain intensity. Immunoreactivity to Ki-67 was "low" if nuclear staining of tumor cells was <20% (Ki-67 LI-low) and "high" if ≥20% (Ki-67 LI-high), as previously described (21) . For each tissue sample, H-score for p53 and Ki-67 LI was averaged across evaluable TMA tissue cores.
Statistical Analysis
To determine the association of p53 expression with clinico-pathological features, cutoff scores were determined by ROC curve analysis. The ROC curve is a plot of the sensitivity and
(1-specificity) for an outcome at each value of the protein expression score. An H-score can therefore be selected from the curve such that a cutoff at this value leads to the greatest number of patients correctly classified as with (maximizing sensitivity) and without (maximizing specificity) the clinical end point (22) . ROC curve analysis was performed for stages and survival. The most frequently obtained H-score was selected as the final cutoff score above which tumors should be considered positive for the outcome (23) . χ² tests were used to determine the association between p53 and Ki-67 expression with clinic-pathological characteristics, whereas the Kaplan-Meier method and log-rank test were used for univariate survival analysis.
Cox proportional hazards regression was carried out for multivariable survival analysis. Hazard ratios (HR) and 95% confidence intervals (CI) were obtained. A two sided P value of ≤0.05 was considered statistically significant. All analyses were carried out using SPSS 22.0.
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Results
Clinicopathologic Characteristics
A total of 254 CRC specimens were included in this study. The ages of the patients ranged from 28 to 75 years (median 56 years). The mean follow-up time was 42 months (range 21-68 months). Sixty-eight patients (28%) had relapsed at the time of last follow-up. The metastatic sites included lung (n = 23), liver (n = 22), bone (n = 8), abdomen (n = 7), brain (n = 3), and other organs (n=5).
Correlation of p53 and Ki-67 Expression with Other Clinicopathologic Variables
The association of p53 and Ki-67 expression with clinicopathologic parameters is summarized in Table 1 . The prevalence of positive p53 expression was 63%. Notably, upregulation of p53 was associated with greater tumor size (P=0.001) and high Ki-67 LI (P=0.031).
There was no significant relationship between p53 expression and gender, age, location, 
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Prognostic Significance of p53, Ki-67 and PD-L1 Expression
To evaluate whether p53, Ki-67 and PD-L1 expression in CRC correlates with patients' prognosis, Kaplan-Meier survival curves were constructed using five-year recurrence free survival (RFS). The five-year RFS rate for patients with PD-L1 positive tumors was 60%, and the five-year RFS rate for the PD-L1 negative tumors was 70% (P=0.041, Figure 3A) . Our data also revealed that both positive p53 expression and high Ki-67 labeling index (LI) in CRC was inversely correlated with the five-year RFS (P=0.001 and P=0.003, respectively, Figure 3B , C).
The five-year RFS rate for the p53-positive/Ki-67 LI-high patients was 53% and for the p53-negative/Ki-67 LI-low patients was 89% (P<0.001, Figure 3D ).
Furthermore, Kaplan-Meier analysis was performed in stage II and III CRC patients, respectively. The analysis of patients with stage II CRC showed that the five-year RFS rate for the p53 positive group was 76.7%, which was significantly lower than 91.5% observed for the p53 negative group (P=0.035, Figure 4A ). No significant association between Ki-67 LI or combined p53-Ki-67 status and prognosis was observed in our analysis (P=0.371 and P=0.086, respectively, Figure 4B , C). The analysis of patients with stage III CRC showed that the fiveyear RFS rate for the p53 positive group was 55.4%, which was significantly lower than 77.8% observed for the p53 negative group (P=0.006, Figure 4D ). The five-year RFS rate for the Ki-67 LI-low group was 59.1%, which was significantly lower than 90% observed for the Ki-67 LIhigh group (P=0.013, Figure 4E ). The five-year RFS rate for the p53-positive/Ki-67 LI-high patients was 53% and for the p53-negative/Ki-67 LI-low patients was 89% (P=0.002, Figure 4F ).
However, PD-L1 expression was not a strong prognostic marker in patients with CRC stratified by stages (P=0.494 and P=0.073, respectively). 
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Discussion
Current prognostic indicators are still ineffective for identifying stage II and III CRC patients with high risk of recurrence after resection with curative intent. Current parameters also cannot reliably identify patients who are unlikely to recur after surgery alone. In the present study, we evaluated the immunophenotypes of 254 CRCs, and correlated these findings with the patients' clinical outcomes. We found that PD-LI, Ki-67, and p53 staining each had individual significant prognostic value for patients with stage II and III CRC. However, the combination of p53 and Ki-67 labeling is superior to any individual markers for predicting the outcome for CRC patients after complete resection, especially for those patients who are positive or negative for both immunohistochemical stains.
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10 This is the first study, to our knowledge, investigating these three markers in consecutive patients from a single, well-defined cohort of CRC radical resection patients with long-term follow-up. Mutations of the TP53 tumor suppressor gene play a pivotal role in the progression of CRC. P53 alteration might, therefore, represent a clinically useful marker of prognosis. Many studies have investigated TP53 gene mutations in CRC, but there is still controversy regarding the significance of mutation or the clinical validity of p53 expression for prognosis. In a pooled analysis of prognostic value studies from for p53 alteration 4416 CRC patients in 28 published studies, neither p53 overexpression nor TP53 mutation emerged as a powerful indicator of treatment success (24) . However, another analysis of TP53 mutations from 3,583 CRC patients being followed by 25 different research groups in 17 countries identified tumor site, exon 5 mutation, and adjuvant treatment as important factors in determining the prognostic significance of TP53 genetic alteration for any stage CRC (25) . Available data about the prognostic value of p53 alteration between individual studies are inconclusive (26, 27) , in large part due to the variability between institutions of systematic parameters such as patient selection, amount of tissue studied, and variation in immunostaining criteria.
In this study, all patients were consecutive CRC surgery patients from a single institution with a pathologic stage of II or III. We performed ROC analysis to determine the most discriminatory cutoff score for p53 expression. For the data in this study an H-score ≥ 35 defined positive p53 expression; and an H-score <35 defined negative p53 expression. In our patients, the prevalence of positive p53 expression was 63.0%. Positive p53 staining was associated with increased tumor size and high Ki-67 LI. In view of different patterns of immunoexpression associated with mutant TP53 (28) , further research is required to correlate p53 expression in CRC with mutational analysis in order to establish practical cutoff scores, which can be used to infer When patients were further divided into stage II and III disease, Kaplan-Meier analysis revealed that the five-year RFS rate for the p53 positive group was significantly lower than the p53 negative group in stage II CRC. There was a trend toward a high Ki-67 LI correlation with Discrepancies between our study and previous negative studies for association between Ki-67 or p53 and prognosis or survival may be attributed to the differences in study design, sample size, ethnic populations and stain scoring rules. One limitation of our study is the small size of arrayed samples. The main concern is that due to tumor heterogeneity, biomarker scores 
A C C E P T E D M A N U S C R I P T
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
26
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
27
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
28
